- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01566877
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the safety and tolerability of 14 once daily intravenous (IV) infusions of ascending doses of AVI 7288 compared to matched placebo in healthy male and female subjects.
To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7288 in healthy male and female subjects
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- SNBL Clinical Pharmacology Center, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A subject must meet all of the following criteria to be eligible for this study.
1.Man or woman 18 to 50 years of age, inclusive, at the time of screening. 2.Body mass index 18 kg/m2 to 35 kg/m2, inclusive, at the time of screening and Check-in (Day -1).3.Good general health (no chronic health conditions) as determined by the Investigator.4.Female subjects must be of non-childbearing potential or must, in conjunction with their sexual partner(s), use 2 forms of medically acceptable barrier contraception (e.g., a diaphragm with spermicidal jelly in conjunction with a male condom) during the screening period and for the entire duration of the study including the 28-day post last dose follow-up.5.Male subjects must either be sterile or agree to use, for the entire duration of the study and for 90 days post last dose follow-up, a male condom and the female sexual partner must also use a medically acceptable form of birth control (e.g. oral contraceptives). 6. Male subjects must agree not to donate sperm for at least 90 days after the last infusion of study medication. 7.Able to understand the requirements of the study, to provide written informed consent (as evidenced by signature on an informed consent document that is approved by an Institutional Review Board (IRB), and agree to abide by the study restrictions.
Exclusion Criteria:
A subject who meets any of the following criteria will be excluded from this study.
1.Pregnancy or breastfeeding. 2. A positive urine or blood screen for drugs of abuse, including alcohol. 3.Use of any tobacco- or nicotine-containing products(including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to Check-in (Day -1). 4.Donated blood within 90 days or plasma within 30 days of first dose on Day 1. 5.A positive cotinine test indicating recent nicotine use.6.Active substance abuse or any medical or psychiatric condition that could jeopardize the subject's safety or the subject's ability to comply with the protocol. 7.Use of any medications apart from vitamins, acetaminophen or hormonal contraception within 14 days of first dose on Day 1. Subjects with mild seasonal allergies may use antihistamines at the discretion of the Investigator after discussion with the Sponsor Medical Monitor.8.Participation in any interventional clinical trial within 45 days of first dose on Day 1 (i.e., received any other investigational drug).9. Recipient of an organ transplant (solid or hematopoietic). 10.Prolonged QTcF interval >(440 ms) for males or > 460 ms for females using the average of the triplicate ECGs collected during screening, on Day -1, or just prior to dosing on Day 1. 11.Other clinically significant electrocardiogram (ECG) abnormality, as determined by the Investigator. 12.Any clinically significant abnormal hematology, chemistry, coagulation, or urinalysis value, as determined by the Investigator. 13.Glomerular filtration rate (GFR) of < 90 mL/min, based on the Modification of Diet in Renal Disease equation.14.Urine-albumin-to-creatinine ratio (UACR) > 30 mg/g. 15.Positive test for human immunodeficiency virus (HIV-1 serology) or known HIV infection. 16.Positive result for hepatitis B surface antigen (HBsAg) or for hepatitis C virus (HCV) antibody.17.Use of alcohol-containing foods or beverages within 72 hours prior to Check-in on Day -1.18.Use of caffeine-containing foods or beverages within 24 hours prior to Check-in on Day 1. 19.Febrile illness or significant infection within 48 hours before administration of the first dose of study drug on Day 1.
Note: Inclusion of each subject will be reviewed with a member of Sarepta Therapeutics Clinical Personnel prior to enrollment in the trial. Written approval from a member of Sarepta Therapeutics Clinical Personnel is required prior to randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: AVI-7288
AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges (PMOplus™) that targets Marburg virus nucleoprotein (NP).
AVI-7288 is supplied in 5 mL vials containing 5 mL AVI-7288 at a concentration of 50 mg/mL.
The dose levels of AVI-7288 will vary in four cohort's.
|
Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day. |
PLACEBO_COMPARATOR: Placebo
Placebo control consists of approximately 150 mL normal saline solution administered by IV infusion over 30 minutes once a day for 14 days.
|
Normal Saline Solution (NSS)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The outcome measure is safety, as assessed through adverse event evaluation and serial clinical assessments.
Time Frame: daily during dosing period with follow up on Day 21 and Day 42
|
daily during dosing period with follow up on Day 21 and Day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The outcome measures are Serial PK Day 1 over 24 hours(predose, 10minutes post, 30 minutes post, 1 hour 1.5, 2, 4, 6,. 8, 12,16,24 hours post dose), daily trough level and on Day 14 (last day of dosing) serial PK until 48 hours post last dose.
Time Frame: 2 Weeks
|
Efficacy will not be assessed in a Phase I study.
|
2 Weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mohamed Al-Ibrahim, MD, SNBL
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7288-us-101
- W9113M-10-C-0056 (Other Grant/Funding Number: Transformational Medical Technologies, US Dept. of Defense)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Marburg Hemorrhagic Fever
-
Sarepta Therapeutics, Inc.United States Department of DefenseCompletedMarburg Hemorrhagic FeverUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Marburg Virus DiseaseUganda
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Vaccines | Marburg Virus Disease | Marburgvirus | EbolavirusUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Disease | Marburg DiseaseUnited States
-
Sarepta Therapeutics, Inc.United States Department of DefenseWithdrawnEbola Hemorrhagic FeverUnited States
-
Sarepta Therapeutics, Inc.United States Department of DefenseCompletedEbola Hemorrhagic FeverUnited States
-
Gamaleya Research Institute of Epidemiology and...CompletedEbola Hemorrhagic FeverRussian Federation
-
The Scientific and Technological Research Council...MonitorCROCompleted
-
Tongji HospitalRecruitingHFRS (Hemorrhagic Fever With Renal Syndrome)China
-
National Institute of Allergy and Infectious Diseases...US Military HIV Research ProgramCompleted
Clinical Trials on AVI-7288
-
Imperial College LondonSarepta Therapeutics, Inc.; Department of Health, United KingdomCompletedDuchenne Muscular DystrophyUnited Kingdom
-
Sarepta Therapeutics, Inc.United States Department of DefenseCompletedMarburg Hemorrhagic FeverUnited States
-
Sarepta Therapeutics, Inc.TerminatedCardiovascular Disease | Coronary Artery BypassUkraine
-
Chinese University of Hong KongNot yet recruitingArterial Stiffness
-
Sarepta Therapeutics, Inc.United States Department of DefenseCompletedEbola Hemorrhagic FeverUnited States
-
Sarepta Therapeutics, Inc.Terminated
-
Sarepta Therapeutics, Inc.CompletedWest Nile VirusUnited States
-
Sarepta Therapeutics, Inc.CompletedEncephalitisUnited States
-
Sarepta Therapeutics, Inc.Terminated
-
Sarepta Therapeutics, Inc.TerminatedDuchenne Muscular DystrophyBelgium, France, Italy, United Kingdom